ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Down 23.0% in June

ADMA Biologics, Inc. (NASDAQ:ADMA) was the target of a large drop in short interest in the month of June. As of June 30th, there was short interest totalling 7,270,000 shares, a drop of 23.0% from the June 15th total of 9,440,000 shares. Based on an average daily trading volume, of 2,940,000 shares, the short-interest ratio is presently 2.5 days.

Insider Buying and Selling

In other news, CEO Adam S. Grossman sold 100,000 shares of ADMA Biologics stock in a transaction on Friday, June 14th. The shares were sold at an average price of $10.72, for a total value of $1,072,000.00. Following the completion of the sale, the chief executive officer now owns 2,081,475 shares in the company, valued at approximately $22,313,412. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in shares of ADMA Biologics by 2.7% during the 3rd quarter. Vanguard Group Inc. now owns 12,781,695 shares of the biotechnology company’s stock valued at $45,758,000 after purchasing an additional 336,190 shares during the last quarter. Stonepine Capital Management LLC increased its position in ADMA Biologics by 1.3% during the 4th quarter. Stonepine Capital Management LLC now owns 9,222,617 shares of the biotechnology company’s stock valued at $41,686,000 after buying an additional 118,342 shares in the last quarter. American Century Companies Inc. increased its position in ADMA Biologics by 20.8% during the 3rd quarter. American Century Companies Inc. now owns 4,892,123 shares of the biotechnology company’s stock valued at $17,514,000 after buying an additional 840,761 shares in the last quarter. Mesirow Institutional Investment Management Inc. acquired a new position in shares of ADMA Biologics in the first quarter valued at about $17,221,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of ADMA Biologics by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,636,703 shares of the biotechnology company’s stock valued at $7,398,000 after purchasing an additional 27,357 shares during the period. 75.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Mizuho boosted their price target on shares of ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. HC Wainwright upped their price objective on shares of ADMA Biologics from $7.50 to $10.00 and gave the stock a “buy” rating in a research report on Friday, May 10th. Raymond James increased their price target on shares of ADMA Biologics from $8.00 to $10.00 and gave the company a “strong-buy” rating in a research report on Friday, May 10th. Finally, Cantor Fitzgerald increased their price objective on ADMA Biologics from $10.00 to $15.00 and gave the company an “overweight” rating in a research note on Tuesday, July 9th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $12.25.

ADMA Biologics Price Performance

ADMA opened at $12.78 on Monday. ADMA Biologics has a 12-month low of $3.06 and a 12-month high of $12.80. The stock has a fifty day simple moving average of $10.15 and a two-hundred day simple moving average of $7.25. The company has a market cap of $2.96 billion, a price-to-earnings ratio of -639.00 and a beta of 0.55. The company has a current ratio of 5.21, a quick ratio of 1.86 and a debt-to-equity ratio of 0.91.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Thursday, May 9th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.03. ADMA Biologics had a positive return on equity of 17.24% and a negative net margin of 1.29%. The business had revenue of $81.90 million for the quarter, compared to analysts’ expectations of $77.28 million. During the same period last year, the firm posted ($0.03) earnings per share. The business’s revenue for the quarter was up 43.9% on a year-over-year basis. Research analysts predict that ADMA Biologics will post 0.35 earnings per share for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.